Recent Clinical Experience with Oncolytic Viruses

Title:Recent Clinical Experience with Oncolytic Viruses

Volume: 13 Issue: 9

Author(s): O. G. Donnelly, F. Errington-Mais, R. Prestwich, K. Harrington, H. Pandha, R. Vile and A. A. Melcher

Affiliation:

Keywords: Oncolytic virus, adenovirus, measles, reovirus, vaccinia, cancer, replication-competent viruses

Abstract: There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia) have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach. Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.

Cite this article as:

G. Donnelly O., Errington-Mais F., Prestwich R., Harrington K., Pandha H., Vile R. and A. Melcher A., Recent Clinical Experience with Oncolytic Viruses, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958904